An interventional study of Gastric Electrical Stimulator in Gastroparesis Nondiabetic, sponsored by Indiana University. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-01.
Sponsored by Indiana University · Not applicable, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Gastroparesis by Indiana University — 7 open to participants now, 8 under way, none of them phase 3. Gastroparesis · Indiana University.
Among the 15 studies in Gastroparesis by Indiana University, this one is the only one that started in 2026, is one of 7 with no phase, and was the 14th registered.
323 studies on the registry are indexed under Gastroparesis; 75 are open to participants now.
Browse Gastroparesis studies →7 of the 15 studies in Gastroparesis by Indiana University are open now, in 1 country. Recruiting first, the newest first:
Indiana University · Sites in United States
Ages 18+
Indiana University · Sites in United States
Ages 18+ · Healthy volunteers
Indiana University · Sites in United States
Indiana University · Sites in United States
Ages 6 mo–90 yrs · Healthy volunteers
Indiana University · Sites in United States
Ages 18–80
By country, each count listing its studies:
Of the 49 Gastroparesis studies recruiting now, 25 (51%) set no upper age limit and 14 (29%) stop at 75 or younger; 8 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 32 is below the median of 42 across 215 interventional studies indexed under Gastroparesis.
Median enrollment 32 across the 8 interventional studies, 158 across the 7 observational. Of the 5 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Indiana University is the lead sponsor of 991 studies on the registry; 202 are open to participants now.
Of its 150 completed or terminated interventional studies of FDA-regulated products, 118 (79%) have results posted.
3 of the studies in Gastroparesis by Indiana University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04506593Indiana UniversityIndiana University Gastrointestinal Motility Diagnosis Registry | 2026-11 |
| NCT02165059Indiana UniversityGI Neuromuscular Pathology Prospective Registry | 2026-12 |
| NCT04282317Indiana UniversityMagnetic Resonance Imaging of the Brain and Stomach in Healthy Volunteers and Gastroparesis | 2026-12-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 15 studies in Gastroparesis by Indiana University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this study is to determine how much effect turning off an individual's Gastric Electrical Stimulator (GES) for up to four hours will have on levels of insulin, C-peptide, GLP-1 and glucose levels.
Up to thirty-two adult patients with gastroparesis who have undergone implantation of a gastric stimulation device at least three months prior may participate in this study, which will be completed at a single study visit.
The study consists of two groups, an EXPERIMENTAL group that undergoes turning off the GES and a CONTROL group that does not undergo the turning off of the GES. The subjects are randomized to either the control or experimental group.
After an overnight fast, consented and eligible patients are placed in the supine position on a hospital bed, and an intravenous line is inserted and capped. EKG electrodes will be placed on the chest, arms/legs, behind each ear and just under the jaw on each side to record cardiac and vagal nerve activity.
The study consists of three separate and consecutive periods:
A 5-ml sample of blood will be collected from each patient after placement of the flexible IV catheter secured with tape, and after the Baseline, and Recovery study periods. During the Experimental period a blood sample is withdrawn after 30 minutes and then again at the 1-hour, 2-hour, 3-hour and 4-hour intervals through a flexible IV catheter secured with tape, with the possibility of up to 8 blood draws over the duration of the study. EKG and vagal nerve activity will be recorded continuously through the 3 study periods.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This group of subjects will have their GES interrogated and observed as well as having the device turned off for the duration of the experiment. The device will then be re-interrogated and turned back on at the end of the experiment.
Device: Gastric Electrical Stimulator
This group of subjects will undergo the same procedures as the experimental group, except that their GES will not be turned off during the experimental period.
Device will either be turned off for the duration of the experimental period.
Also known as: GES
Change in serum insulin
To define the effect of prolonged four-hour withdrawal of gastric electrical stimulation on serum insulin.
Time frame: Day 1
Change in serum C-peptide
To define the effect of prolonged four-hour withdrawal of gastric in human subjects. Insulin and C-peptide are co-primary end points.
Time frame: Day 1
Changes in serum glucose
To compare the changes in serum GLP-1 and glucose levels after 4-hour withdrawal of gastric electrical stimulation to a control group that does not undergo withdrawal of gastric electrical stimulation.
Time frame: Day 1
Changes in serum GLP-1
To compare the changes in serum GLP-1 and glucose levels after 4-hour withdrawal of gastric electrical stimulation to a control group that does not undergo withdrawal of gastric electrical stimulation.
Time frame: Day 1
Plan to share: No
Started Jul 2026 (actual). Primary completion is estimated for Jul 2028, 24 months after the start.
Of 56 non-industry interventional studies with no phase under Gastroparesis, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 59. This study's planned 24 months is below that.
Counting every sponsor, half of 65 studies reached it within 28 months; a quarter within 11 and three quarters within 58.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.